Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) Files An 8-K Regulation FD Disclosure
Item7.01.
| Regulation FD Disclosure. |
On May15, 2017, Aerie Pharmaceuticals, Inc. (the Company) issued
a press release announcing the Prescription Drug User Fee Act
(PDUFA) goal date for the Companys new drug application (NDA) for
its product candidate, RhopressaTM (netarsudil ophthalmic solution)
0.02%. A copy of the press release is furnished as Exhibit 99.1
hereto and is hereby incorporated by reference into this
Item7.01.
The information in this Item7.01 (including Exhibit 99.1) is
being furnished, not filed, to Regulation FD. Accordingly, the
information in this Item7.01 will not be incorporated by
reference into any registration statement filed by the Company
under the Securities Act of 1933, as amended, unless specifically
identified therein as being incorporated therein by reference.
The furnishing of the information in this Item7.01 is not
intended to, and does not, constitute a determination or
admission by the Company that this information is material or
complete, or that investors should consider this information
before making an investment decision with respect to any security
of the Company.
| Item9.01. | Financial Statements and Exhibits. |
| (d) | Exhibits. |
The following exhibit relating to Item7.01 shall be deemed to be
furnished, and not filed:
| 99.1 | Press Release dated May15, 2017. |
About Aerie Pharmaceuticals, Inc. (NASDAQ:AERI)
Aerie Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s primary product candidates are Rhopressa and Roclatan. Its product candidates are designed to lower intraocular pressure (IOP) in patients with open-angle glaucoma and ocular hypertension. Rhopressa is a once-daily eye drop and a triple-action netarsudil ophthalmic solution. The active ingredient in Rhopressa acts through the inhibition of both Rho Kinase (ROCK) and norepinephrine transporter (NET). Roclatan is a once-daily, quadruple-action product candidate and is a fixed-dose combination of Rhopressa and latanoprost, which is a prescribed drug for the treatment of patients with glaucoma. The Company is engaged in conducting Phase III clinical trials for Rhopressa and Roclatan. Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) Recent Trading Information
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) closed its last trading session down -0.50 at 39.05 with 281,381 shares trading hands.
